Arginine

證據等級: L5

預測適應症: 1 個

Arginine: From Amino Acid Supplement to Gastroparesis

One-Sentence Summary

L-Arginine (DB00125) is a conditionally essential amino acid traditionally administered as a nutritional supplement and used in the management of inborn urea cycle disorders. The TxGNN model predicts it may be effective for Gastroparesis (delayed gastric emptying), a condition with significant unmet therapeutic need. Current evidence supporting this direction consists of 1 registered clinical trial (not directly relevant to arginine therapy) and 10 publications, all of which are animal mechanistic studies — no human clinical data is yet available.

Quick Overview

Item	Content
Original Indication	Nutritional amino acid supplementation; urea cycle disorder support
Predicted New Indication	Gastroparesis
TxGNN Prediction Score	99.42%
Evidence Level	L4
Canada Market Status	✗ Not Marketed
Number of DINs	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Detailed mechanism of action data is not available in this Evidence Pack. Based on known biochemistry, L-Arginine is the sole endogenous substrate for nitric oxide synthase (NOS), the enzyme that synthesises nitric oxide (NO). In the gastrointestinal tract, NO serves as the primary inhibitory neurotransmitter of the enteric nervous system, mediating relaxation of the pyloric sphincter and gastric fundus smooth muscle — both of which are prerequisites for normal gastric emptying.

Gastroparesis is characterised at the mechanistic level by impaired nitrergic (NO-mediated) relaxation of the gastric outlet. This has been demonstrated across multiple animal models: reduced expression of neuronal NOS (nNOS) is consistently found in diabetic rodent stomachs, nNOS-knockout mice develop spontaneous gastroparesis, and impaired pyloric nitrergic relaxation has been confirmed in a Parkinson’s disease rat model (PMID 35380456). The most directly relevant finding comes from PMID 25057793, which showed that glucocorticoid administration depletes L-Arginine in mice, thereby inducing gastroparesis — and that this effect was abolished when arginine was restored. This creates a biologically coherent rationale: if gastroparesis can arise from arginine deficiency, arginine supplementation could theoretically reverse the defect by replenishing the NO precursor pool.

That said, this entire mechanistic chain currently rests on animal models. The step from “arginine depletion causes gastroparesis in mice” to “arginine supplementation improves gastroparesis in humans” has not been validated in any clinical study. Key unknowns include whether oral arginine adequately reaches enteric neurons, whether the nitrergic deficit is the dominant mechanism in human gastroparesis subtypes (diabetic, idiopathic, post-surgical), and whether systemic NO effects could present safety concerns in specific populations.

Clinical Trial Evidence

The evidence search returned one registered trial; it is not directly relevant to L-Arginine therapy for gastroparesis.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01702051	N/A	Unknown	150	Autologous pancreatic islet cell transplantation after pancreatectomy to prevent post-surgical diabetes — unrelated to arginine supplementation; included due to overlapping gastroparesis co-morbidity context only

No clinical trials directly evaluating L-Arginine supplementation for gastroparesis were identified. This is the primary gap limiting progression to higher evidence levels.

Literature Evidence

All ten identified publications are animal mechanistic or preclinical studies. No human clinical trials, observational studies, or systematic reviews were retrieved.

PMID	Year	Type	Journal	Key Findings
25057793	2014	Animal mechanistic study	Endocrinology	Most relevant. Glucocorticoids deplete L-Arginine in mice, directly inducing gastroparesis; the effect was abrogated in GR(dim) mutant mice, confirming arginine depletion as a causal mechanism
23639814	2013	Animal mechanistic study	Am J Physiol Gastrointest Liver Physiol	Tetrahydrobiopterin (BH4) deficiency — which impairs NO synthesis downstream of arginine — causes gastroparesis in newborn mice, further supporting the NO precursor pathway
35380456	2022	Animal mechanistic study	Am J Physiol Gastrointest Liver Physiol	Impaired nitrergic relaxation of the pyloric sphincter in a 6-OHDA Parkinson’s disease rat model; confirms that nNOS-mediated NO signalling is essential for pyloric motility
18312542	2008	Animal study	Neurogastroenterol Motil	Reduced nNOS expression in jejunum of spontaneously diabetic BB-rats; inhibitory neurotransmitter dysfunction demonstrated independently of vagal control
19023028	2009	Animal study	Am J Physiol Gastrointest Liver Physiol	Synchronized gastric electrical stimulation restores gastric accommodation via the nitrergic pathway in vagotomised dogs, demonstrating NO pathway plasticity
18322959	2008	Animal study	World J Gastroenterol	Ghrelin and GHRP-6 improve gastric motility in diabetic mice with gastroparesis; indirect evidence of motility pathway modifiability
31984783	2020	Animal study	Am J Physiol Gastrointest Liver Physiol	Sacral nerve stimulation improves gastric accommodation via spinal afferent–vagal efferent circuit in rats
21193530	2011	Animal study	Am J Physiol Gastrointest Liver Physiol	Hyperglycaemia inhibits gastric motility through nodose ganglia K(ATP) channel activation in rats; characterises glycaemic contribution to diabetic gastroparesis
33867519	2021	Case report	Am J Case Rep	MELAS patient (m.3243A>G) with gastroparesis; lactate normalisation with lifestyle changes — indirect relevance; highlights mitochondrial energy metabolism overlap
8194696	1994	Animal study	Gastroenterology	Antigen challenge in sensitised rats causes delayed gastric emptying; early characterisation of gastroparesis mediators

Canada Market Information

L-Arginine (DB00125) has no Health Canada–approved pharmaceutical products with a Drug Identification Number (DIN). It is available commercially in Canada as a natural health product (NHP) under NPN licensing, but not as a regulated prescription or over-the-counter drug.

No DIN-registered products are on record. Market entry as a pharmaceutical indication would require full Health Canada New Drug Submission or a clinical trial authorisation (CTA).

Safety Considerations

All safety fields (key warnings, contraindications, drug interactions) are unavailable in the current Evidence Pack.

Please refer to the package insert and Health Canada product monograph for safety information. Key areas to investigate prior to any clinical study include: renal and hepatic metabolism of arginine, potential interactions with antihypertensives (due to NO-mediated vasodilation), contraindications in herpes simplex virus-prone patients (arginine promotes viral replication), and precautions in patients with guanidinoacetate methyltransferase deficiency.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic hypothesis linking L-Arginine supplementation to gastroparesis improvement is scientifically coherent and grounded in the established role of the L-Arginine → NOS → NO pathway in gastric motility. However, all supporting evidence is currently at preclinical level (Evidence Level L4), with no human pharmacodynamic, safety, or efficacy data available. The prediction score from TxGNN is high (99.42%), suggesting strong network-level biological plausibility, but this cannot substitute for clinical validation.

To proceed to “Proceed with Guardrails,” the following is needed:

Human proof-of-concept data: At least one Phase 1 or Phase 2 clinical study evaluating oral or intravenous L-Arginine supplementation in gastroparesis patients, with gastric emptying scintigraphy as an endpoint
Safety profile completion: Obtain TFDA package insert, Health Canada product monograph, and complete DrugBank safety data (warnings, contraindications, DDI profile)
Mechanistic validation in humans: Measurement of gastric mucosal NO levels or plasma arginine/citrulline ratios in gastroparesis patients to confirm the arginine-depletion hypothesis translates from mouse to human
Dose and formulation strategy: Determine whether enteral arginine achieves sufficient enteric nerve exposure, or whether a targeted delivery approach is needed
Subgroup definition: Identify which gastroparesis aetiology (glucocorticoid-induced, diabetic, idiopathic) is most likely to respond based on the arginine-depletion mechanism
Regulatory pathway assessment: Define whether a Health Canada CTA or natural health product amendment pathway is more appropriate for a first-in-human study in Canada
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.